Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953378 | 0.82 | NPC1 (0.36) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL514136 | 0.81 | MAPT (0.50) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL23037579 | 0.81 | MAPT (0.42) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL181067 | 0.81 | ALDH1A1 (0.55) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL1255394 | 0.78 | HSD17B10 (0.58) | MAPTLMNAPOLBALDH1A1KDM4E | |
| SCHEMBL27976004 | 0.78 | MAPT (0.43) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL515447 | 0.78 | PPIA (0.43) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL31000747 | 0.77 | PPIA (0.45) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL2913776 | 0.77 | ALDH1A1 (0.45) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL6276445 | 0.77 | PPIA (0.45) | MAPTGAALMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | claimed |
| EP-0066378-B1 | PHARMACEUTICAL SPIRO-HYDANTOIN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-02 | — | — | EP | claimed |
| US-4386100-A | COMPLICATIONS OF DIABETES OR GALACTOSEMIA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-05-31 | — | — | US | claimed |
| EP-0066378-A1 | Pharmaceutical spiro-hydantoin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-08 | — | — | EP | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-0066378-B1 | PHARMACEUTICAL SPIRO-HYDANTOIN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-02 | — | — | EP | disclosed |
| US-4386100-A | COMPLICATIONS OF DIABETES OR GALACTOSEMIA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-05-31 | — | — | US | disclosed |
| EP-0066378-A1 | Pharmaceutical spiro-hydantoin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | MAPT 4824/4885GAA 4215/4885LMNA 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.